Role of Tissue and Systemic Hypoxia in Obesity and Type 2 DiabetesView this Special Issue
Research Article | Open Access
Helena H. Chowdhury, Jelena Velebit, Nataša Radić, Vito Frančič, Marko Kreft, Robert Zorec, "Hypoxia Alters the Expression of Dipeptidyl Peptidase 4 and Induces Developmental Remodeling of Human Preadipocytes", Journal of Diabetes Research, vol. 2016, Article ID 7481470, 9 pages, 2016. https://doi.org/10.1155/2016/7481470
Hypoxia Alters the Expression of Dipeptidyl Peptidase 4 and Induces Developmental Remodeling of Human Preadipocytes
Dipeptidyl peptidase 4 (DPP4), a transmembrane protein, has been identified in human adipose tissue and is considered to be associated with obesity-related type 2 diabetes. Since adipose tissue is relatively hypoxic in obese participants, we investigated the expression of DPP4 in human preadipocytes (hPA) and adipocytes in hypoxia, during differentiation and upon insulin stimulation. The results show that DPP4 is abundantly expressed in hPA but very sparsely in adipocytes. During differentiation in vitro, the expression of DPP4 in hPA is reduced on the addition of differentiation medium, indicating that this protein can be hPA marker. Long term hypoxia altered the expression of DPP4 in hPA. In in vitro hypoxic conditions the protease activity of shed DPP4 is reduced; however, in the presence of insulin, the increase in DPP4 expression is potentiated by hypoxia.
Dipeptidyl peptidase 4 (DPP4) is a 110 kDa transmembrane glycoprotein. A soluble form of DPP4 (sDPP4) in the circulation is the result of proteolytic cleavage of the membrane bound form . DPP4 has a rare protease activity, cleaving N-terminal x-Pro dipeptide from selected proteins. Besides enzymatic inactivation of incretins, DPP4 also mediates degradation of several growth factors, neuropeptides, chemokines, and vasoactive peptides, which results in alterations in their biological activity, often by altering their receptor specificity .
Altered DPP4 activity has been reported in a number of diseases, including type 2 diabetes [3, 4] and tumor biology [2, 5–7]. It is thought to be associated with sensitivity to anticancer agents in haematologic malignancies and is involved in the development of various chronic liver diseases . DPP4 was considered as a therapeutic target for type 2 diabetes as it degrades incretins: glucagon-like peptide- (GLP-) 1 and gastric inhibitory peptide (GIP). Both hormones cause an increase in insulin secretion. DPP4 inhibitors target the enzyme activity of DPP4, thus prolonging the insulinotropic effects of incretins .
In patients with type 2 diabetes acute hypoxia increases the glucose uptake into the tissue [10, 11]; however, prolonged exposure to hypoxia has been associated with induction of insulin resistance in adipose tissue [12, 13]. More specifically, adipose tissue hypoxia, which develops with the onset of obesity [14, 15], has been linked to the development of insulin resistance and type 2 diabetes by decreasing insulin signaling pathways . It was reported that DPP4 is expressed in preadipocytes and in adipocytes , indicating that adipose tissue might be a major source of circulating DPP4. Therefore, an altered expression of adipose tissue DPP4 could be linked to the development of type 2 diabetes; however the factors that alter the expression of DPP4 are poorly understood.
In the present study we developed a confocal microscopy assay to study the expression of DPP4 in human preadipocytes (hPA). We evaluated DPP4 expression during the differentiation of human preadipocytes into adipocytes and studied how insulin affects the expression and activity of released DPP4. The results show that in hypoxic conditions the protease activity of shed DPP4 is reduced. Interestingly, insulin increases DPP4 expression and this is potentiated by hypoxia.
2. Experimental Procedures
Dulbecco’s modified Eagle’s medium/Ham’s F12 (DMEM/F12), l-glutamine, dexamethasone, isobutylmethylxanthine (IBMX), biotin, d-pantothenic acid hemicalcium salt, phosphate-buffered saline (PBS), bovine serum albumin (BSA), trypsin-EDTA, Trypan Blue, and goat serum were purchased from Sigma (St. Louis, MO). Insulin was purchased from Novo Nordisk (Bagsvaerd, Denmark). Fetal bovine serum (FBS) was obtained from Biochrom (Berlin, Germany). Rosiglitazone maleate was obtained from GlaxoSmithKline (Worthing, UK). Dimethyl sulfoxide (DMSO) was purchased from Merck Schuchardt (Hohenbrunn, Germany). Antibiotic-antimycotic mixture was purchased from Gibco (Invitrogen Corporation, NY). Paraformaldehyde was purchased from Thermo Scientific, USA.
2.2. Primary Preadipocyte Maintenance and Differentiation Procedure
Preadipocytes (human subcutaneous) were purchased from ZenBio, Inc. (Research Triangle Park, NC). Cells were cultured under standard conditions (at 37°C, humidified atmosphere, 5% CO2) in PM medium. For each set of experiments, cells were seeded on coverslips in uniform density, which was provided by counting cells before seeding. For differentiation into adipocytes we used the protocol from ZenBio. The start of the differentiating procedure was marked as day 0. On indicated days the 16 h conditioned 1% BSA/PBS medium was collected, filtered (0.2 μm), and analyzed for enzymatic activity and quantification of sDPP4. On day 21 60–70% of cells were fully differentiated, indicated by the accumulation of lipid droplets (not shown). The cells were than subjected to immunolabeling protocol or trypsinized and counted using a hemocytometer (improved Neubauer type). Three separate samples were prepared for each time point.
2.3. Hypoxia Treatment In Vitro
For the study of DPP4 expression under hypoxic conditions, preadipocytes were cultured in a hypoxic chamber (Billups-Rothenberg, Dell Mar, CA), flushed twice at a 2 h interval for 4 min with a gas mixture consisting of 1% O2, 5% CO2, and 94% N2, and incubated for the indicated time at 37°C in a humidified atmosphere.
To identify the expression of HIF-1α and DPP4 in the preadipocytes, primary monoclonal mouse anti-HIF-1α antibodies and primary monoclonal mouse anti-DPP4 antibodies (both Abcam, Cambridge, UK; ab8366 and ab3154) were used and secondary goat anti-mouse antibody conjugated to Alexa Fluor 546 and to Alexa Fluor 488, respectively (A11003 and A11001, Molecular Probes). Cells were washed with PBS and fixed in 2% paraformaldehyde for 20 min, which was sufficient to permeabilise the cell membrane and allow binding of antibody to a total cell protein. Cells were incubated at 37°C in blocking buffer (3% BSA, 10% goat serum in PBS) for 1 h, with primary antibodies for 2 h and with secondary antibodies for 45 min. Subsequently, they were mounted using a Light Antifade kit (Invitrogen).
2.5. Confocal Microscopy
Z-stacks of immunolabeled cells were acquired using a Zeiss LSM 510 confocal microscope through a Plan Apochromatic oil-immersion objective (63x, NA = 1.4), excited by the 488 nm argon laser line and filtered with the 505–560 nm low-pass emission filter and excited by the 543 nm He/Ne laser line and filtered with the 560 nm low-pass emission filter. Images were analyzed quantitatively using LSM 510 software (Carl Zeiss). Eight to 15 markers were manually set to the cell perimeter, and the software interpolated the curve between them. The area above the threshold (20% of the maximal fluorescence intensity) fluorescence intensity relative to the cell cross-sectional area was determined.
2.6. Enzymatic Activity
Peptidase activity of the sDPP4 released from nonpermeabilised cells from the cell surface was determined using the DPPIV/CD26 assay kit for biological samples (Enzo Life Sciences, Plymouth Meeting, PA) according to the manufacturer instructions. The relative fluorescence units for each sample were calculated by plotting the linear region of the change in fluorescence over time and calculating the slope of the line. This was then used with the conversion factor to calculate the activity expressed as pmol/min and divided by the number of cells in individual samples to obtain the values expressed as pmol/min/cell. Data are presented as means ± s.e.m. of all tests ().
The amount of sDPP4 released by the cell at different stages of differentiation and at different oxygenation of the cell atmosphere was quantified by a Human DPPIV/CD26 Quantikine ELISA kit (R&D Systems, Minneapolis MN) following the manufacturer’s recommendations.
3.1. Hypoxia-Mediated Reduction in DPP4 Expression in Single hPA
hPA were cultured in a normoxic chamber (18% pO2) and in a hypoxic chamber (1% pO2). To confirm that these hPA responded to hypoxia, cells were immunolabeled with antibodies against hypoxia-inducible factor-1α (HIF1-α). The results show that exposure to 1% pO2 induced a massive expression of transcriptional factor HIF1-α (Figure 1(b)) and are consistent with previously published data . In cells cultured in 18% pO2, the expression of HIF1-α was negligible (Figure 1(a)). Thus hPA incubated under hypoxic conditions responded physiologically to the lowered pO2.
To examine the expression of DPP4 in a hypoxic environment in vitro and to get insights into short and long term effects of hypoxia, cells were incubated at 1% pO2 for 2 and 9 days and labeled with the anti-DPP4 antibody. The images of the largest optical slice of hPA (Figure 2(a)) were analyzed by determining the percent area of DPP4-labelled part relative to the area of the entire optical slice of a cell. Note that the staining pattern of cells in Figure 2(a) is evenly distributed through the entire cell area. The 2-day exposure to hypoxia significantly reduced the expression density of DPP4 to % compared with cells in normoxia (%; ; Figure 2(b)). Prolonged incubation (9 days) had no further effect on DPP4 expression density in a hypoxic (%) or normoxic environment (%).
3.2. Time-Dependent Increase in the Protease Activity of sDPP4 Is Reduced by Hypoxia
DPP4 is a transmembrane protein; however, it is also active in its soluble form, after shedding the extracellular domain of the protein from the cell’s surface. We investigated the protease activity of sDPP4 in conditioned medium of cells incubated in different oxygenation environments. Significant differences were detected between samples incubated in normoxia for 2 versus 9 days (Figure 2(c)). After 2 days, the activity of DPP4 was fmol/min/cell, increasing to fmol/min/cell after 9 days (). In samples incubated in hypoxia, the activity also appeared to increase from day 2 to day 9, from fmol/min/cell to fmol/min/cell (). In hypoxia on day 2, the DPP4 activity was similar to that in normoxia. However, in the 9-day samples, the activity of DPP4 significantly decreased with hypoxia (). We conclude that although the amount of DPP4 protein that is shed from the cell surface of hPA is insensitive to 2 or 9 days of culture under normoxic and hypoxic conditions, we detected a significant time-dependent increase in DPP4 protease activity in normoxic controls; the increase was relatively reduced by hypoxia.
3.3. Differentiation-Mediated Decrease in DPP4 Expression in Adipocytes Is Potentiated by Hypoxia
We studied the influence of the state of differentiation of adipocytes on the DPP4 expression pattern. In normoxia DPP4 expression is variable but tends to decline as a function of time (Figure 3(a)), especially at the induction of differentiation, and is barely detectable on mature adipocytes on day 21 (Figure 3(a)). In hypoxia (Figure 3(b)), the expression of DPP4 also decreased continuously. Comparison of differentiation-dependent DPP4 expression between both oxygenation conditions revealed that, with the exception of day 21, DPP4 expression density is significantly lower under hypoxic conditions at all stages of differentiation (), consistent with data in Figure 2.
We also studied the concentration of sDPP4 in conditioned medium of cells, which tended to decrease as a function of differentiation (Figure 4(a)). With only a few exceptions (see # on Figure 4(a)), the concentration of sDPP4 seemed to decrease at a similar rate under normoxic and hypoxic conditions during differentiation.
Investigation of the protease activity of sDPP4 in the culture medium revealed that as in Figure 4(a) a similar trend of decrease during differentiation was found (Figure 4(b)). To confirm that the protease activity of sDPP4 is significantly lower under hypoxic versus normoxic conditions, we correlated the concentration of sDPP4 protein and its protease activity in normoxic and hypoxic conditions (Figure 4(c)). The slopes of the regression lines are significantly different, indicating that hypoxic conditions significantly enhance the differentiation-dependent reduction of sDPP4 protease activity, relative to the protein content of DPP4.
3.4. Insulin Enhances the Shedding and Protease Activity of sDPP4 in Normoxic and Hypoxic Preadipocytes
Preadipocytes incubated for 2 days at 18% and 1% pO2 were stimulated with insulin (100 nM) for 30 min. In normoxia, insulin significantly increased DPP4 expression in preadipocytes (%; Figure 5(a)) versus stimulation with vehicle only (%; ). A similar increase was observed in hypoxia; insulin significantly increased DPP4 expression (%) versus controls (%; ).
To study shedding, we also examined the concentration of sDPP4 in the conditioned medium (Figure 5(b)) of cells stimulated with insulin. Hypoxia did not influence the sDPP4 concentration in controls or insulin-stimulated cells. However, insulin treatment significantly increased DPP4 protein shedding in normoxia () and in hypoxia (). Under both oxygenation conditions, we recorded a pronounced effect of insulin treatment on sDPP4 protease activity in the culture medium (Figure 5(c)). In normoxia, insulin significantly increased protease activity ( fmol/min/cell) compared to nonstimulated cells ( fmol/min/cell; ). In hypoxia, insulin stimulation also increased the activity of shed protein ( fmol/min/cell) compared to controls ( fmol/min/cell; ). These results indicate that hypoxic conditions increase insulin-mediated expression, shedding, and protease activity of DPP4 in preadipocytes.
4.1. Is DPP4 a Marker for Differentiation Status of Adipocytes?
DPP4 is abundantly expressed in hPA, while in mature adipocytes we found very modest, if any, expression of DPP4 (Figure 3). The significantly lower expression of DPP4 in mature adipocytes could not be explained with differences in cell size between both stages of differentiation, since the difference is not statistically significant (not shown). These results suggest that during differentiation from hPA into adipocytes cells gradually suppress the DPP4 expression. If this reduction in DPP4 in hPA is associated with differentiation into adipocytes in vivo, then DPP4 may well represent a marker for differentiation status. Therefore, like Pref-1, a stemness marker for preadipocytes, DPP4 is also robustly expressed in hPA: the higher the expression of DPP4 in preadipocytes, the higher the stem-like character of these cells. In support of this, DPP4 is abundantly expressed in cultured hPA (Figure 2), and during differentiation DPP4 expression declines (Figure 3). It is unlikely that DPP4 downexpression during differentiation is associated with a response to some of the factors in the differentiation medium added, as the DPP4 downexpression started prior to the addition of differentiation medium (Figures 3 and 4), at a stage when cells reached confluence. Although these results contrast with the report where cancer cells were studied by Abe et al. , the most probable explanation for the reduction of DPP4 in the (pre)adipocytes is the cell-to-cell contact-induced differentiation process into mature adipocytes that contain very modest amounts of DPP4.
DPP4 was found to be expressed in a variety of cell types [19, 20], from which it is also shed and sDPP4 may influence the shedding of membrane bound DPP4 from preadipocytes that were investigated in this study.
Current experiments revealed that the stage of differentiation of hPA into adipocytes can be assessed by monitoring the DPP4 density in cells, which can be considered as a developmental or differentiation marker, reporting the relatively undifferentiated stage of these cells. Consistent with this, it has recently been demonstrated that hypoxia inhibits adipogenesis through the HIF1α pathway [21, 22]. Hypoxia arrests preadipocytes in an undifferentiated state, thereby maintaining their stemness [23, 24].
The reduction in DPP4 in single differentiating cells is further supported by the determination of the concentration of sDPP4 and its enzymatic activity. Both parameters exhibit a differentiation-dependent decrease (Figures 4(a) and 4(b)) and this is consistent with the view that the soluble protein arises from the shedding of DPP4 from the plasma membrane. DPP4 has been shown to move from the cytoplasm to the cell surface rapidly and consequently the protein amount on the cell membrane is steadily proportional to the total cell protein . The correlation between the concentration of sDPP4 and its activity (Figure 4(c)) shows that in hypoxia the activity is reduced by almost a factor of three relative to the concentration of soluble protein. One possible explanation would be that hypoxia lowers pH of cells. DPP4 enzymatic activity is pH dependent with the optimum at 7.8 . A lower pH in hypoxic conditions would result in lower DPP4 activity. However, the activity assay was performed with buffered solution maintaining constant pH during the assay; therefore we can exclude the pH influence at the time of measurements of enzymatic activity. Although pH was not quantitatively measured during hypoxia it was observed qualitatively with pH indicator in the cell medium with no obvious changes during incubation in hypoxia, indicating that pH of the cell medium did not change significantly.
Hypoxia-related increase of preadipocyte stemness could be an additional mechanism in the development of insulin resistance. The results imply that in obesity-related hypoxia DPP4 is abundantly expressed, contributing to the reduction in insulin activity and thereby to the onset of insulin resistance in these subjects.
4.2. Insulin Increases DPP4 Expression Density in hPA
Most gastrointestinal (GI) hormones involved in satiety regulation and glucose metabolism, especially through regulation of insulin secretion, are hydrolyzed and inactivated by DPP4 . Thus DPP4 action reduces the amount of insulin secretion. This mechanism of action is well exploited by the development of a class of antidiabetic drugs that inhibit DPP4. But little is known about how insulin influences the expression of DPP4. The results of this study demonstrate that at single-cell level insulin significantly increases DPP4 expression in hPA in a rapid manner (30 min) by about 35%. Under hypoxic conditions, this increase was 63% relative to control (Figure 5(a)). These results indicate that DPP4 is also regulated by insulin but unlike hypoxia, which renders DPP4 expression, the rapid effect of insulin is most likely posttranscriptional.
Insulin induces DPP4 expression on cells which in turn deactivated GI hormones, thereby inhibiting the stimulation of insulin secretion. In agreement with this, incubation of cells with insulin for 5 and 24 h resulted in decreased DPP4 expression to baseline level (not shown). This is probably due to insulin receptor internalization and deactivation of insulin signaling. As expected, sDPP4 in culture medium and its protease activity also significantly increased after 30 min of insulin action in both oxygenation environments.
This study shows that human preadipocytes express DPP4 abundantly and this expression decreases in the course of differentiation into mature adipocytes. Therefore, DPP4 can be considered a differentiation marker highlighting the stemness properties of preadipocytes. The strong inhibition of DPP4 protease activity by hypoxia and the insulin-mediated increase in DPP4 indicate that DPP4 represents an important marker for early detection of insulin resistance.
Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.
The human preadipocytes cell line was a kind gift from Professor Jürgen Eckel, German Diabetes Center, Dusseldorf, Germany. The study was supported in part by the Slovenian Research Agency (Grants J3 3632 to Robert Zorec, J3 4051 to Robert Zorec, J3 4146 to Marko Kreft, and P3 310 to Robert Zorec).
- R. Yazbeck, G. S. Howarth, and C. A. Abbott, “Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?” Trends in Pharmacological Sciences, vol. 30, no. 11, pp. 600–607, 2009.
- C. A. Abbott, D. M. T. Yu, E. Woollatt, G. R. Sutherland, G. W. McCaughan, and M. D. Gorrell, “Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8,” European Journal of Biochemistry, vol. 267, no. 20, pp. 6140–6150, 2000.
- B. Gallwitz, “The evolving place of incretin-based therapies in type 2 diabetes,” Pediatric Nephrology, vol. 25, no. 7, pp. 1207–1217, 2010.
- L. K. Phillips and J. B. Prins, “Update on incretin hormones,” Annals of the New York Academy of Sciences, vol. 1243, pp. E55–E74, 2011.
- P. A. Havre, M. Abe, Y. Urasaki, K. Ohnuma, C. Morimoto, and N. H. Dang, “The role of CD26/dipeptidyl peptidase IV in cancer,” Frontiers in Bioscience, vol. 13, no. 5, pp. 1634–1645, 2008.
- M. Javidroozi, S. Zucker, and W.-T. Chen, “Plasma seprase and DPP4 levels as markers of disease and prognosis in cancer,” Disease Markers, vol. 32, no. 5, pp. 309–320, 2012.
- A. Varona, L. Blanco, I. Perez et al., “Expression and activity profiles of DPP IV/CD26 and NEP/CD10 glycoproteins in the human renal cancer are tumor-type dependent,” BMC Cancer, vol. 10, article 193, 2010.
- M. Itou, T. Kawaguchi, E. Taniguchi, and M. Sata, “Dipeptidyl peptidase-4: a key player in chronic liver disease,” World Journal of Gastroenterology, vol. 19, no. 15, pp. 2298–2306, 2013.
- B. Ahrén, “DPP-4 inhibitors,” Best Practice & Research in Clinical Endocrinology and Metabolism, vol. 21, no. 4, pp. 517–533, 2007.
- R. Mackenzie, N. Maxwell, P. Castle, G. Brickley, and P. Watt, “Acute hypoxia and exercise improve insulin sensitivity in individuals with type 2 diabetes,” Diabetes/Metabolism Research and Reviews, vol. 27, no. 1, pp. 94–101, 2011.
- W. Schobersberger, P. Schmid, M. Lechleitner et al., “Austrian Moderate Altitude Study 2000 (AMAS 2000). The effects of moderate altitude (1,700 m) on cardiovascular and metabolic variables in patients with metabolic syndrome,” European Journal of Applied Physiology, vol. 88, no. 6, pp. 506–514, 2003.
- N. Halberg, T. Khan, M. E. Trujillo et al., “Hypoxia-inducible factor 1α induces fibrosis and insulin resistance in white adipose tissue,” Molecular and Cellular Biology, vol. 29, no. 16, pp. 4467–4483, 2009.
- C. Regazzetti, P. Peraldi, T. Grémeaux et al., “Hypoxia decreases insulin signaling pathways in adipocytes,” Diabetes, vol. 58, no. 1, pp. 95–103, 2009.
- N. Hosogai, A. Fukuhara, K. Oshima et al., “Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation,” Diabetes, vol. 56, no. 4, pp. 901–911, 2007.
- M. E. Rausch, S. Weisberg, P. Vardhana, and D. V. Tortoriello, “Obesity in C57BL/6J mice is characterized by adipose tissue hypoxia and cytotoxic T-cell infiltration,” International Journal of Obesity, vol. 32, no. 3, pp. 451–463, 2008.
- D. Lamers, S. Famulla, N. Wronkowitz et al., “Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome,” Diabetes, vol. 60, no. 7, pp. 1917–1925, 2011.
- B. Wang, I. S. Wood, and P. Trayhurn, “Hypoxia induces leptin gene expression and secretion in human preadipocytes: differential effects of hypoxia on adipokine expression by preadipocytes,” Journal of Endocrinology, vol. 198, no. 1, pp. 127–134, 2008.
- M. Abe, P. A. Havre, Y. Urasaki et al., “Mechanisms of confluence-dependent expression of CD26 in colon cancer cell lines,” BMC Cancer, vol. 11, article 51, 2011.
- S. Mentzel, H. B. P. M. Dijkman, J. P. H. F. Van Son, R. A. P. Koene, and K. J. M. Assmann, “Organ distribution of aminopeptidase A and dipeptidyl peptidase IV in normal mice,” Journal of Histochemistry and Cytochemistry, vol. 44, no. 5, pp. 445–461, 1996.
- M. D. Gorrell, “Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders,” Clinical Science, vol. 108, no. 4, pp. 277–292, 2005.
- Z. Yun, H. L. Maecker, R. S. Johnson, and A. J. Giaccia, “Inhibition of PPARγ2 gene expression by the HIF-1-regulated gene DEC1/Stra13: a mechanism for regulation of adipogenesis by hypoxia,” Developmental Cell, vol. 2, no. 3, pp. 331–341, 2002.
- Q. Lin, Y.-J. Lee, and Z. Yun, “Differentiation arrest by hypoxia,” The Journal of Biological Chemistry, vol. 281, no. 41, pp. 30678–30683, 2006.
- Y. Yamamoto, M. Fujita, Y. Tanaka et al., “Low oxygen tension enhances proliferation and maintains stemness of adipose tissue-derived stromal cells,” BioResearch Open Access, vol. 2, no. 3, pp. 199–205, 2013.
- P. Trayhurn, “Hypoxia and adipose tissue function and dysfunction in obesity,” Physiological Reviews, vol. 93, no. 1, pp. 1–21, 2013.
- L. Baricault, J. A. M. Fransen, M. Garcia et al., “Rapid sequestration of DPP IV/CD26 and other cell surface proteins in an autophagic-like compartment in Caco-2 cells treated with forskolin,” Journal of Cell Science, vol. 108, part 5, pp. 2109–2121, 1995.
- T. Yoshimoto, M. Fischl, R. C. Orlowski, and R. Walter, “Post-proline cleaving enzyme and post-proline dipeptidyl aminopeptidase. Comparison of two peptidases with high specificity for proline residues,” The Journal of Biological Chemistry, vol. 253, no. 10, pp. 3708–3716, 1978.
- W. Kim and J. M. Egan, “The role of incretins in glucose homeostasis and diabetes treatment,” Pharmacological Reviews, vol. 60, no. 4, pp. 470–512, 2008.
Copyright © 2016 Helena H. Chowdhury et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.